COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control’s independent advisory committee will meet May 12 for what’s expected to be a discussion of Pfizer’s request to authorize the emergency use of its COVID-19 vaccine on children aged 12 to 15.
The Centers for Medicare & Medicaid Services Office of Minority Health will host a May 13 webinar on building COVID-19 vaccine confidence.
The Food and Drug Administration updated its webpage on the performance of SARS-CoV-2 serology tests authorized for emergency use to help health care providers interpret these antibody test results for their patients.
A Centers for Disease Control and Prevention assessment affirms the ability of the two authorized mRNA COVID-19 vaccines to prevent hospitalization in fully vaccinated adults ages 65 and older.
The Centers for Disease Control and Prevention announced relaxed guidance for mask wearing, stating that individuals fully vaccinated against COVID-19 no longer need to wear masks outdoors, except in certain crowd settings and venues.
An independent Centers for Disease Control and Prevention advisory committee recommended immediate resumption of the administration of Johnson & Johnson’s COVID-19 vaccine in the U.S.
The Food and Drug Administration revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
The Food and Drug Administration today revoked its emergency use authorization for the COVID-19 monoclonal antibody therapy bamlanivimab when administered alone.
Drug overdose deaths in the United States rose by an estimated 29% between September 2019 and September 2020 to 90,237, according to preliminary data released by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices holds an emergency meeting on the Johnson & Johnson (Janssen) COVID-19 vaccine to review reports that six women aged 18-48 experienced a rare but serious condition involving blood clots and low…